Analysis of the Dynamics of Cognitive Impairments and Expression of Caspase Cascade Genes in Preclinical Stages of Parkinsonism Modeled Using α-Synuclein Oligomers.

M A Gruden, V I Inokenteva, O A Solovieva, N P Mikhailova, A M Ratmirov, V V Sherstnev, Z I Storozheva

Abstract read

In one paragraph

Article in Bulletin of experimental biology and medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

M A GrudenFederal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies, Moscow, Russia. mgruden@mail.ru.

V I InokentevaFederal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies, Moscow, Russia.

O A SolovievaFederal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies, Moscow, Russia.

N P MikhailovaFederal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies, Moscow, Russia.

A M RatmirovFederal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies, Moscow, Russia.

V V SherstnevFederal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies, Moscow, Russia.

Z I StorozhevaFederal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies, Moscow, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The behavioral effects of α-synuclein oligomers were studied at various times after its chronic intranasal administration to 75-day-old C57BL/6J mice in comparison with the dynamics of changes in the transcriptional activity of caspases genes (Casp9, Casp8, and Casp3) in the hippocampus, frontal cortex, and cerebellum. The negative effects of α-synuclein oligomers on exploratory activity and short-term memory in the novel object recognition test were most pronounced after 90 days from the end of administration, while after 1 and 270 days, partial compensation of the studied cognitive functions was observed. Analysis of the expression of caspase genes suggests that early compensatory mechanisms are associated with suppression of the effector caspase-3 gene expression along with increased activity of the genes encoding initiator caspases-9 and -8. Late compensation processes are associated with a decrease in the activity of initiator caspases in the frontal cortex and cerebellum.

Indexed as

alpha-SynucleinCaspase 3Caspase 8Caspase 9CerebellumCognitive DysfunctionHippocampusMice, Inbred C57BLAnimalsDisease Models, AnimalFrontal LobeMaleMemory, Short-TermMiceParkinsonian Disordersalpha-SynucleinCasp3 protein, mouseCasp8 protein, mouseCasp9 protein, mouseCaspase 3Caspase 8Caspase 9Casp9, Casp8, Casp3 genescognitive activitydelayed effectsmiceα-synuclein oligomers

Identifiers

PMID39259467

DOI10.1007/s00415-022-11531-y

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.